Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Prostate Cancer

  Free Subscription


Articles published in Mod Pathol

Retrieve available abstracts of 21 articles:
HTML format



Single Articles


    January 2024
  1. MIYAMOTO H, Teramoto Y, Numbere N, Wang Y, et al
    Prostate cancer risk stratification by simple scoring of the current pT3 lesions: A proposal for a new pathologic T-staging system.
    Mod Pathol. 2024 Jan 22:100429. doi: 10.1016/j.modpat.2024.100429.
    PubMed     Abstract available


    July 2023
  2. CHEN Y, Loveless IM, Nakai T, Newaz R, et al
    Convolutional Neural Network Quantification of Gleason Pattern 4 and Association With Biochemical Recurrence in Intermediate-Grade Prostate Tumors.
    Mod Pathol. 2023;36:100157.
    PubMed     Abstract available


  3. SALLES DC, Mendes AA, Han M, Partin AW, et al
    ERG Status at the Margin Is Associated With Biochemical Recurrence After Radical Prostatectomy With Positive Surgical Margins.
    Mod Pathol. 2023;36:100147.
    PubMed     Abstract available


    June 2023
  4. PATEL P, Harmon S, Iseman R, Ludkowski O, et al
    Artificial Intelligence-Based PTEN Loss Assessment as an Early Predictor of Prostate Cancer Metastasis After Surgery: a Multi-Center Retrospective Study.
    Mod Pathol. 2023 Jun 19:100241. doi: 10.1016/j.modpat.2023.100241.
    PubMed     Abstract available


  5. ERAK E, Oliveira LD, Mendes AA, Dairo O, et al
    Predicting Prostate Cancer Molecular Subtype with Deep Learning on Histopathologic Images.
    Mod Pathol. 2023 Jun 10:100247. doi: 10.1016/j.modpat.2023.100247.
    PubMed     Abstract available


    February 2023
  6. MEHRA R, Shah T, Liu CJ, Plouffe KR, et al
    Highly Recurrent IDH1 Mutations in Prostate Cancer with Psammomatous Calcification (PCWPC).
    Mod Pathol. 2023 Feb 22:100146. doi: 10.1016/j.modpat.2023.100146.
    PubMed     Abstract available


  7. VORMITTAG-NOCITO E, Acosta AM, Agarwal S, Narayan KD, et al
    In-Depth Comparison of Genetic Variants Demonstrates a Close Relationship Between Invasive and Intraductal Components of Prostate Cancer.
    Mod Pathol. 2023;36:100130.
    PubMed     Abstract available


    November 2022
  8. YU Y, Lajkosz K, Finelli A, Fleshner N, et al
    Impact of cribriform pattern 4 and intraductal prostatic carcinoma on National Comprehensive Cancer Network (NCCN) and Cancer of Prostate Risk Assessment (CAPRA) patient stratification.
    Mod Pathol. 2022;35:1695-1701.
    PubMed     Abstract available


    August 2022
  9. CHAN E, McKenney JK, Hawley S, Corrigan D, et al
    Analysis of separate training and validation radical prostatectomy cohorts identifies 0.25 mm diameter as an optimal definition for "large" cribriform prostatic adenocarcinoma.
    Mod Pathol. 2022;35:1092-1100.
    PubMed     Abstract available


    May 2022
  10. SHAH RB, Palsgrove DN, Desai NB, Gagan J, et al
    Enrichment of "Cribriform" morphologies (intraductal and cribriform adenocarcinoma) and genomic alterations in radiorecurrent prostate cancer.
    Mod Pathol. 2022 May 23. pii: 10.1038/s41379-022-01093.
    PubMed     Abstract available


    April 2022
  11. JUNG M, Jin MS, Kim C, Lee C, et al
    Artificial intelligence system shows performance at the level of uropathologists for the detection and grading of prostate cancer in core needle biopsy: an independent external validation study.
    Mod Pathol. 2022 Apr 29. pii: 10.1038/s41379-022-01077.
    PubMed     Abstract available


  12. CAHILL LC, Rosen S, Yoshitake T, Wu Y, et al
    Real-time diagnosis and Gleason grading of prostate core needle biopsies using nonlinear microscopy.
    Mod Pathol. 2022;35:539-548.
    PubMed     Abstract available


    December 2021
  13. SCHOMIG-MARKIEFKA B, Pryalukhin A, Hulla W, Bychkov A, et al
    Quality control stress test for deep learning-based diagnostic model in digital pathology.
    Mod Pathol. 2021;34:2098-2108.
    PubMed     Abstract available


    November 2021
  14. PAN CC, Epstein JI
    Reexamining the molecular findings in specialized stromal tumors of the prostate.
    Mod Pathol. 2021;34:2080-2081.
    PubMed    


  15. ACOSTA AM, Sholl LM, Marino-Enriquez A, Dal Cin P, et al
    In Response to "Reexamining the molecular findings in specialized stromal tumors of the prostate".
    Mod Pathol. 2021;34:2082-2083.
    PubMed    


    September 2021
  16. FERGUSON DC, Mata DA, Tay TK, Traina TA, et al
    Androgen receptor splice variant-7 in breast cancer: clinical and pathologic correlations.
    Mod Pathol. 2021 Sep 30. pii: 10.1038/s41379-021-00924.
    PubMed     Abstract available


  17. CHATRIAN A, Colling RT, Browning L, Alham NK, et al
    Artificial intelligence for advance requesting of immunohistochemistry in diagnostically uncertain prostate biopsies.
    Mod Pathol. 2021;34:1780-1794.
    PubMed     Abstract available


  18. ACOSTA AM, Sholl LM, Dickson BC, McKenney JK, et al
    Re-evaluating tumors of purported specialized prostatic stromal origin reveals molecular heterogeneity, including non-recurring gene fusions characteristic of uterine and soft tissue sarcoma subtypes.
    Mod Pathol. 2021;34:1763-1779.
    PubMed     Abstract available


    June 2021
  19. HANSUM T, Hollemans E, Verhoef EI, Bangma CH, et al
    Comedonecrosis Gleason pattern 5 is associated with worse clinical outcome in operated prostate cancer patients.
    Mod Pathol. 2021 Jun 26. pii: 10.1038/s41379-021-00860.
    PubMed     Abstract available


    March 2021
  20. BULTEN W, Balkenhol M, Belinga JA, Brilhante A, et al
    Artificial intelligence assistance significantly improves Gleason grading of prostate biopsies by pathologists.
    Mod Pathol. 2021;34:660-671.
    PubMed     Abstract available


    April 2020
  21. ZHU MMT, Burugu S, Gao D, Yu J, et al
    Evaluation of glucocorticoid-induced TNF receptor (GITR) expression in breast cancer and across multiple tumor types.
    Mod Pathol. 2020 Apr 29. pii: 10.1038/s41379-020-0550.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.